Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

Author： Pratley Richard E.   Salsali Afshin  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.4, 2007-04, pp. : 919-931

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

By Tahrani Abd   Piya Milan   Barnett Anthony  

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 736-736

Springer Publishing Company

Access to resources Recommend Favorite

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

By Karasik Avraham   Aschner Pablo   Katzeff Harvey   Davies Michael J.   Stein Peter P.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 489-496

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 427-437

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 3, 2015-03 ,pp. : 292-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

By  

Current Drug Safety, Vol. 6, Iss. 5, 2011-11 ,pp. : 304-309

Bentham Science Publishers

Access to resources Recommend Favorite